Genmab went public in October 2000. Genmab is listed on Nasdaq Copenhagen under the symbol GEN and is a member of the OMX Nordic Large Cap Index, the OMX Copenhagen Benchmark Index and the OMX Copenhagen 20 Cap Index (OMXC20CAP). Our ID code/ISIN is DK0010272202. Genmab has also established a sponsored Level 1 American Depositary Receipt (ADR) program, under which Genmab ADRs can be traded on the US over-the-counter (OTC) market under the symbol GMXAY.
Genmab has approximately 63,000 registered shareholders. There are 60,350,056 shares outstanding. Each share has a nominal value of DKK 1, resulting in a share capital of DKK 60,350,056.
Genmab is headquartered in Copenhagen, Denmark, has its research laboratories in Utrecht the Netherlands and has an administrative office in Princeton, NJ, USA.
Genmab has three subsidiaries: Genmab B.V. and Genmab Holding B.V. in the Netherlands and Genmab US, Inc. in the United States.
On December 31, 2015 Genmab had 186 full time employees.
Genmab develops antibody therapeutics. Genmab's main focus is on products that can be used to treat cancer, although the company has also developed products for autoimmune disease and CNS indications.
Genmab has two products on the market: DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the United States in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent. DARZALEX is indicated in Europe for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Arzerra (ofatumumab) is approved in the U.S. in combination with chlorambucil to treat previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. Arzerra is approved in Europe in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. It is also approved in the U.S. for extended treatment of patients who are in complete or partial response after at least two lines of therapy for current or prgressive CLL. Arzerra is also approved to treat CLL in patients who are refractory to fludarabine and alemtuzumab in all major markets.
Yes, Genmab has a number of products in clinical and pre-clinical development. Refer to our product pipeline for more information.
You can find our interim financial reports and annual reports in the Financial reports section of this website.
Genmab uses 5 different technologies to create antibodies:
- The UltiMAb® transgenic mouse technology, licensed from Medarex (a subsidiary of Bristol-Myers Squibb), is used to create fully human antibodies.
- Our proprietary DuoBody technology platform enables us to create human bispecific antibodies that bind to two different targets.
- Our UniBody technology platform which produces antibody fragments with only one binding arm.
- Antibody Drug Conjugate (ADC) technology, licensed from Seattle Genetics, combines antibodies with anti-cancer agents to selectively target tumor cells.
Genmab’s novel proprietary HexaBodyTM platform is designed to increase the potency of antibodies. The technology has the potential to enhance antibody therapeutics for a broad range of applications in cancer and infectious diseases.
PricewaterhouseCoopers is Genmab's auditor.
Genmab uses two principal law firms, Shearman & Sterling LLP and Kromann Reumert.
You may contact Rachel Gravesen, Senior Vice President, Investor Relations & Communications by phone at +45 3344 7720 or by email
Yes, Genmab has established a sponsored Level 1 ADR program. Click here for more information.